CDXS - Up Over 500% in the Last 5 Years Can This Biotech Continue Its Hot Streak?
Less waste, increased yield, better performance. This is the mantra of biologic manufacturer Codexis (NASDAQ: CDXS) , which produces optimized enzymes to enhance the yield of current chemistry methods by traditional pharmaceutical companies. By providing a more sustainable and efficient alternative to today's practices, this enzyme manufacturing biotech has seen its share price appreciate over 500% in the last five years.
image source: Getty Images.
From 2006 to 2012, the company was focused on advancing biofuels with its enzymes. It was so focused on this effort that 51% of its revenue in 2012 was derived from a research and development collaboration with Royal Dutch Shell . When the agreement was terminated in August 2012, Codexis saw its full-year revenue melt from $88.3 million in 2012 to $31.9 million in 2013.
For further details see:
Up Over 500% in the Last 5 Years, Can This Biotech Continue Its Hot Streak?